These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22551892)

  • 1. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer.
    Gioulbasanis I; Pallis A; Vlachostergios PJ; Xyrafas A; Giannousi Z; Perdikouri IE; Makridou M; Kakalou D; Georgoulias V
    Lung Cancer; 2012 Aug; 77(2):383-8. PubMed ID: 22551892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer.
    Wang D; Duan L; Tu Z; Yan F; Zhang C; Li X; Cao Y; Wen H
    Chemotherapy; 2016; 61(4):217-22. PubMed ID: 26905743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer.
    Crumley AB; Stuart RC; McKernan M; McDonald AC; McMillan DC
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e325-9. PubMed ID: 17645468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF; Chen ZW; Lu S
    Chin Med J (Engl); 2009 Oct; 122(20):2472-6. PubMed ID: 20079162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer.
    Sharma R; Zucknick M; London R; Kacevska M; Liddle C; Clarke SJ
    Clin Colorectal Cancer; 2008 Sep; 7(5):331-7. PubMed ID: 18794066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.
    Di Maio M; Lama N; Morabito A; Smit EF; Georgoulias V; Takeda K; Quoix E; Hatzidaki D; Wachters FM; Gebbia V; Tsai CM; Camps C; Schuette W; Chiodini P; Piccirillo MC; Perrone F; Gallo C; Gridelli C
    Eur J Cancer; 2010 Mar; 46(4):735-43. PubMed ID: 20045311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer.
    Ramsey S; Lamb GW; Aitchison M; Graham J; McMillan DC
    Cancer; 2007 Jan; 109(2):205-12. PubMed ID: 17149754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy.
    Jiang AG; Lu HY
    J Chemother; 2015 Feb; 27(1):35-9. PubMed ID: 24716851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma.
    Kobayashi T; Teruya M; Kishiki T; Endo D; Takenaka Y; Tanaka H; Miki K; Kobayashi K; Morita K
    Surgery; 2008 Nov; 144(5):729-35. PubMed ID: 19081014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison between single-agent and platinum-doublet chemotherapy in elderly patients with non-small cell lung cancer].
    Tamiya A; Naito T; Takahashi T; Endo M; Yamamoto N
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1897-901. PubMed ID: 20948252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival.
    Read JA; Choy ST; Beale PJ; Clarke SJ
    Nutr Cancer; 2006; 55(1):78-85. PubMed ID: 16965244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W; Gurubhagavatula S; Liu G; Park S; Neuberg DS; Wain JC; Lynch TJ; Su L; Christiani DC
    Clin Cancer Res; 2004 Aug; 10(15):4939-43. PubMed ID: 15297394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of POLK polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
    Shao M; Jin B; Niu Y; Ye J; Lu D; Han B
    Cell Biochem Biophys; 2014 Nov; 70(2):1227-37. PubMed ID: 24948471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer.
    Sharma R; Hook J; Kumar M; Gabra H
    Eur J Cancer; 2008 Jan; 44(2):251-6. PubMed ID: 18155897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
    Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
    Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
    Eckardt JR; Bentsion DL; Lipatov ON; Polyakov IS; Mackintosh FR; Karlin DA; Baker GS; Breitz HB
    J Clin Oncol; 2009 Apr; 27(12):2046-51. PubMed ID: 19289620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ; Fernandes AL; Pereira JR; Curtis JR; Santoro IL
    Lung Cancer; 2006 Aug; 53(2):171-6. PubMed ID: 16757059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.